Patient and Survivor Programs
The access and care you need
Patient Emergency Fund
Through the Patient Emergency Fund, Lung Cancer Initiative offers financial assistance to provide support for lung cancer patients to help with healthy food costs, transportation and other non-medical expenses to assist with emergencies associated with a lung cancer diagnosis.
Directions to Apply
- Fill out or online application or download the application. Call the LCI office at 919-784-0410 for assistance.
- Bring the application to your next appointment to fill out with a representative from your cancer center or have your cancer center fill out the online application.
- Follow the instructions on the application to return to LCI
- All questions must be answered in order to be considered for fulfillment.
Guidelines
- Applicants must be a resident of North Carolina.
- Applicants must currently be in treatment for lung cancer.
- Each applicant can receive one stipend per calendar year.
Patient Emergency Funds Still Available! Apply Today!
Tomma Hargraves Gas Card Program
The Lung Cancer Initiative Tomma Hargraves Gas Card Program provides assistance to lung cancer patients who are seeking treatment including clinical trials. The goal of the program is to lessen the financial burden for patients so they can receive appropriate lung cancer treatment by providing gas cards. To be eligible for a gas card, the applicant must be a resident of North Carolina and currently undergoing treatment for lung cancer. An application must be completed and signed by both the applicant and the healthcare facility.
Directions to Apply
1. Download the application below or call the LCI office at 919-784-0410 to request an
application to be mailed to you.
2. Bring the application to your next appointment to fill out with a representative from your cancer center.
3. Utilize the instructions on the application to return it to LCI.
4. All questions must be answered in order to be considered for fulfillment
“As a lung cancer survivor, I felt this need to find a tangible way to support patients on a very local level. It’s been gratifying to see how successful this gas card program has been at getting people to treatment.”
Questions about our gas card program? Interested in supporting this program? Contact Chief Mission Delivery Officer, Jenni Danai.
Thank you to our Gas Card program sponsors!
Survivor Engagement Events
Survivor Engagement Events are programs designed to build a community of survivors who offer support and camaraderie to one another. Whether you were diagnosed yesterday or 20 years ago, you are welcome and encouraged to attend! Most of these events are social. Occasionally, guest speakers or doctors will join and share relevant information for survivors. Each June, LCI hosts an annual Survivors Day Celebration for lung cancer survivors and their families.
Meet and fellowship with other lung cancer survivors at our Online Survivor Luncheons which are on the second Thursday of every month. This is a perfect time for us to come together from across the state and socialize while we’re apart.
Reserve your spot by viewing the luncheon dates below and registering! These events will be held on Zoom.
View 2024 Dates
View 2025 Dates
Thank you to our luncheon sponsors!
Wellness Retreats
LCI offers an annual wellness retreat to provide lung cancer survivors with coping mechanisms proven to enhance quality of life after a lung cancer diagnosis. We assemble a professional wellness team to provide survivors with evidence-based, integrative techniques to battle stress and tools to monitor their well-being. Most importantly, this retreat connects survivors to a community of others who truly understand what they are going through.
This year, we hosted our 7th annual Lung Cancer Survivor Wellness Retreat on September 20 – 22, 2024. If you are interested in attending the retreat in 2025, please contact Cheryl Lecroy, Lung Cancer Initiative Survivor Liaison.
Therapy Assistance Programs
AstraZeneca
Lung cancer is at the forefront of AstraZeneca’s research and development focus. Our expanding portfolio aims to provide medicines that can improve outcomes at every stage of the disease. But we know if we are to make meaningful progress for lung cancer patients, we cannot work alone. We have partnered with the International Association for the Study of Lung Cancer (IASLC), the Global Lung Cancer Coalition (GLCC), and Guardant Health to form the Lung Ambition Alliance. Together we are taking urgent action to double five-year survival in lung cancer globally by 2025 – prioritising research and projects that increase screening, deliver innovative medicine and improve quality care
(AstraZeneca, 2023)
Boehringer Ingelheim
Boehringer Ingelheim
For assistance with our program, please call our toll-free number Monday – Friday from 8:30 a.m. – 6:00 p.m. Eastern time:
BI Cares Patient Assistance Program (includes several medicines) 1-800-556-8317
BI Cares Patient Assistance Program- Gilotrif 1-855-297-5904
BI Cares Patient Assistance Program- Ofev 1-855-297-5906
Lung Cancer Therapy: Gilotrif® and Ofev®
Bristol-Myers Squibb
Bristol-Myers Squibb
Lung Cancer Therapy: Empliciti®, Nulojix ®, Onureg ®, Opdivo ® and Opdivo Combination,
Orencia ®, Sprycel ®, Yervoy ®
Support Center: 1-800-861-0048
8:00 a.m. to 8:00 p.m. EST, Monday – Friday
Bristol-Myers Squibb (BMS) is committed to helping patients get better access to their
prescribed BMS medications. That’s why we offer the BMS Access Support® program, which
provides resources that help patients with their reimbursement challenges.
Eli Lilly & Co
Eli Lilly & Co
Call 1-866-472-8663
Monday – Friday, 8:00 a.m. – 10:00 p.m. EST
Lung Cancer Therapies: ALIMTA® (pemetrexed for injection), CYRAMZA® (ramucirumab),
Portrazza® (necitumumab), RetevmoTM (selpercatinib)
Lilly TruAssist is the collection of Lilly patient assistance programs that offer assistance to help people obtain the Lilly medicines they need. This site includes all of Lilly’s patient assistance programs with individual program details.
G1 Therapeutics
Call: 1-833-418-6663
Therapy: COSELA™ (trilaciclib)
G1 to One™ Patient Support Program is here to help eligible patients who need COSELA™ (trilaciclib) gain access to it. We can help you with getting started on COSELA quickly, benefits investigations, out-of-pocket assistance, and getting COSELA for people who are uninsured for underinsured.
Genentech
Genentech
Call: (877) 436-3683
Lung Cancer Therapies: Avastin® (bevacizumab), ROZLYTREK™ (entrectinib), TECENTRIQ®
(atezolizumab), ALECENSA® (alectinib), COTELLIC® (cobimetinib)
Genentech Access Solutions is here to help when a Genentech medicine is prescribed. We offer a full range of programs and services to meet the needs of patients and health care professionals. What patients need for access—from benefits investigations through patient assistance options—is available through Genentech Access Solutions.
Janssen
Call: 1-833-9119-3510
Therapy: RYBREVANT®
The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization. JJPAF gives eligible patients free prescription medicines donated by Johnson & Johnson. Patients may be eligible if they don’t have insurance, if their medicine is not covered by insurance, or if they have Medicare coverage and can’t pay for their medicine.
Merck
Merck
Call: 855-257-3932
Lung Cancer Therapy: Keytruda (pembrolizumab)
The Merck Patient Assistance Program provides certain medicines free of charge to eligible patients.
Novartis
Lung Cancer Therapy: Zykadia® (ceritinib)
http://www.us.zykadia.com/patient/support.jsp
Call: 1-888-669-6682
Co-pay assistance is available for eligible patients with a prescription for ZYKADIA.
Novartis
Call 1-800-282-7630
Monday – Friday, 9:00 a.m. – 10:00 p.m. EST
Lung Cancer Therapies: Tabrecta(capmatinib)
The Novartis Patient Navigator Program is staffed by a team of specialists who are available to support you during your treatment journey. Once enrolled in the program, you will receive a series of phone calls from a specially trained navigator who will help you understand the results of your benefits investigation, educate you about financial assistance options, and help you get started on your Novartis medicine(s).
Pfizer
Pfizer
Call: 1-866-706-2400
Lung Cancer Therapy: Xalkori®(crizotinib) LORBRENA® (lorlatinib) VIZIMPRO® (dacomitinib)
XALKORI® (crizotinib) VIZIMPRO® (dacomitinib)
Pfizer RxPathways, formerly Pfizer Helpful Answers, is a comprehensive assistance program that provides eligible patients with a range of support services, including insurance counseling, co-pay assistance,* and access to medicines for free or at a savings.
Takeda
Call: 1-844-817-6468
Lung Cancer Therapy: EXKIVITY(mobocertinib) and ALUNBRIG(brigatinib)
From finding financial assistance that may be right for you to understanding your disease, Takeda Oncology Here2Assist™ can provide the information you need throughout your treatment.
Virtual Reimbursement Resource
NCCN Patient and Payment Assistance
If your treatment is not listed, another resource is the National Comprehensive Cancer Network’s Virtual Reimbursement Resource Room, which aims to respond to the ever-evolving challenges for clinicians and others that work with patients with cancer. Select a cancer or supportive care indication or select a reimbursement program to learn about reimbursement help and services available to you to help your practice mitigate reimbursement challenges.
Did you know that survivors are able to attend LCI events for free? No registration fee required! Check out our upcoming events and join us for a celebration of survivorship and to meet other survivors and families impacted by lung cancer
Peer-to-Peer Program
Receiving a lung cancer diagnosis can be an overwhelming experience. LCI created the Peer-to-Peer Program so lung cancer patients would have ongoing support from a peer who has walked in their shoes.
This program provides reciprocal support between lung cancer survivors. Peers will share their experience and hopefully ease the stress, anxiety and fear that comes with a lung cancer diagnosis.
Interested in becoming apart of the program? Contact Cheryl Lecroy.